Background. Ceftaroline is a new broad-spectrum cephalosporin with in vitro activity against Gram-positive pathogens, including MRSA, and common Gram-negative pathogens. It is approved for the treatment of acute complicated bacterial skin and skin-structure infections (SSSIs) and community-acquired bacterial pneumonia.
Objective. To determine in vitro activity of ceftaroline and other clinically available antimicrobials against major bacterial pathogens from different regions of Russian Federation.
Materials and Methods. A total of 2778 consecutive, non-duplicate isolates were collected during multicentre microbiological in vitro study from 36 geographically distinct cities of Russia during 2008–2012.